<![CDATA[Co-Management, REMS Changes, and What’s Next for CAR T in Multiple Myeloma]]>

Summary

Matthew J. Frigault, MD, of Mass General Brigham Cancer Institute discusses CAR T-cell therapy for multiple myeloma, stressing that community providers should view it as a co-management strategy. The piece also touches on REMS changes and future directions, but the excerpt provides no specific data.